Avalo Therapeutics (AVTX) – Investment Analysts’ Weekly Ratings Changes

Avalo Therapeutics (NASDAQ: AVTX) recently received a number of ratings updates from brokerages and research firms:

• 5/14/2026 – Avalo Therapeutics had its price target lowered by Citizens Jmp from $62.00 to $55.00. They now have a “market outperform” rating on the stock.
• 5/14/2026 – Avalo Therapeutics had its price target lowered by Wedbush from $40.00 to $34.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Avalo Therapeutics had its price target raised by Mizuho from $39.00 to $45.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Avalo Therapeutics had its price target lowered by HC Wainwright from $40.00 to $35.00. They now have a “buy” rating on the stock.
• 5/11/2026 – Avalo Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $60.00 price target on the stock, up from $48.00.
• 5/6/2026 – Avalo Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/6/2026 – Avalo Therapeutics had its price target raised by Citizens Jmp from $52.00 to $62.00. They now have a “market outperform” rating on the stock.
• 5/6/2026 – Avalo Therapeutics had its price target raised by Wedbush from $29.00 to $40.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Avalo Therapeutics had its price target raised by BTIG Research from $40.00 to $58.00. They now have a “buy” rating on the stock.
• 4/13/2026 – Avalo Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.
• 4/9/2026 – Avalo Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $48.00 price target on the stock.
• 4/8/2026 – Avalo Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Avalo Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $48.00 price target on the stock.
• 4/6/2026 – Avalo Therapeutics is now covered by Citizens Jmp. They set an “outperform” rating and a $52.00 price target on the stock.
• 3/29/2026 – Avalo Therapeutics was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 3/25/2026 – Avalo Therapeutics had its price target raised by HC Wainwright from $25.00 to $40.00. They now have a “buy” rating on the stock.
• 3/24/2026 – Avalo Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.

Insider Transactions at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. The trade was a 87.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher Ryan Sullivan sold 8,458 shares of the company’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total value of $110,715.22. Following the completion of the sale, the chief financial officer owned 8,880 shares in the company, valued at $116,239.20. This trade represents a 48.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 138,078 shares of company stock worth $2,501,346. Company insiders own 4.46% of the company’s stock.

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.